5—FU治疗药物监测现状及其与结直肠癌化疗毒性相关性的研究进展(5)
[20] CICCOLINI J，GROSS E，DAHAN L，et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities： hype or hope？[J]. Clin Colorectal Cancer，2010，9(4)： 224-228.
[21] CAPITAIN O，BOISDRON-CELLE M，POIRIER AL，et al. The influcence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer[J]. Pharmacogenomics J，2008，8(4)： 256-267.
[22] MURPHY RF，BALIS FM，POPLACK DG. Stability of 5-fluorouracil in whole blood and plasma[J]. Clin Chem，1987，33(12)：2299-2300.
, 百拇医药
[23] 龍子君，刘庆，李苏，等.纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较[J].江苏医药，2017，43(18)：1306-1310.
[24] KLINE CL，SCHICCITANO A，ZHU J，et al. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early-or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens[J]. Clin Colorectal Cancer，2014，13(2)： 119-126.
[25] ADJEI AA，REID JM，DIASIO RB，et al.Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors[J]. J Clin Oncol，2002，20(6)：1683-1691.
, 百拇医药
[26] 董秋美，黄赛花，郑伟华，等.高效液相色谱法检测结直肠癌患者5-FU血药浓度的临床意义[J].中华肿瘤防治杂志，2010，17(18)：1476-1478、1481.
[27] 鞠颖慧，周琰，彭颖斐，等. 液相色谱-串联质谱检测血浆5-氟尿嘧啶方法的建立及其临床应用[J].中华医学杂志，2016，96(10)：817-821.
[28] DERISSEN EJ，HILLEBRAND MJ，ROSING H，et al. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil[J]. J Pharm Biomedical Anal，2015. DOI：10.1016/j.jpba.2015. 02.051.
, 百拇医药
[29] BEUMER JH，BOISDRON-CELLE M，CLARKE W，et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer[J]. Ther Drug Monit，2009，31(6)：688-694.
[30] 宋卫峰，王雷，蔡讯，等. 晚期结直肠癌患者氟尿嘧啶剂量与血药浓度和生存的关系[J]. 肿瘤，2013，33(9)： 820-826.
[31] SANTINI J，MILANO G，THYSS A，et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer[J]. Br J Cancer，1989 ，59(2)：287-290.
, 百拇医药
[32] CAPITAIN O，ASEVOAIA A，BOISDRON-CELLE M，et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing： a phaseⅡ，proof-of- concept study[J]. Clin Colorectal Cancer，2012，11(4)：263-267.
[33] WILHELM M，MUELLER L，MILLER MC，et al. Prospective，multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice[J]. Clin Colorectal Cancer，2016，15(4)：381-388., 百拇医药(张娟 吴东媛 刘铎 董梅)
[21] CAPITAIN O，BOISDRON-CELLE M，POIRIER AL，et al. The influcence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer[J]. Pharmacogenomics J，2008，8(4)： 256-267.
[22] MURPHY RF，BALIS FM，POPLACK DG. Stability of 5-fluorouracil in whole blood and plasma[J]. Clin Chem，1987，33(12)：2299-2300.
, 百拇医药
[23] 龍子君，刘庆，李苏，等.纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较[J].江苏医药，2017，43(18)：1306-1310.
[24] KLINE CL，SCHICCITANO A，ZHU J，et al. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early-or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens[J]. Clin Colorectal Cancer，2014，13(2)： 119-126.
[25] ADJEI AA，REID JM，DIASIO RB，et al.Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors[J]. J Clin Oncol，2002，20(6)：1683-1691.
, 百拇医药
[26] 董秋美，黄赛花，郑伟华，等.高效液相色谱法检测结直肠癌患者5-FU血药浓度的临床意义[J].中华肿瘤防治杂志，2010，17(18)：1476-1478、1481.
[27] 鞠颖慧，周琰，彭颖斐，等. 液相色谱-串联质谱检测血浆5-氟尿嘧啶方法的建立及其临床应用[J].中华医学杂志，2016，96(10)：817-821.
[28] DERISSEN EJ，HILLEBRAND MJ，ROSING H，et al. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil[J]. J Pharm Biomedical Anal，2015. DOI：10.1016/j.jpba.2015. 02.051.
, 百拇医药
[29] BEUMER JH，BOISDRON-CELLE M，CLARKE W，et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer[J]. Ther Drug Monit，2009，31(6)：688-694.
[30] 宋卫峰，王雷，蔡讯，等. 晚期结直肠癌患者氟尿嘧啶剂量与血药浓度和生存的关系[J]. 肿瘤，2013，33(9)： 820-826.
[31] SANTINI J，MILANO G，THYSS A，et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer[J]. Br J Cancer，1989 ，59(2)：287-290.
, 百拇医药
[32] CAPITAIN O，ASEVOAIA A，BOISDRON-CELLE M，et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing： a phaseⅡ，proof-of- concept study[J]. Clin Colorectal Cancer，2012，11(4)：263-267.
[33] WILHELM M，MUELLER L，MILLER MC，et al. Prospective，multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice[J]. Clin Colorectal Cancer，2016，15(4)：381-388., 百拇医药(张娟 吴东媛 刘铎 董梅)